Sharescart Research Club logo ×
Screener Research Unlisted Startup Funding New IPO New

  • Home
  • /
  • Bliss Gvs Pharma
Join Channel
Consolidated Standalone

Bliss GVS Pharma

₹110 -0.3 | 0.3%

Market Cap ₹1152 Cr.

Stock P/E 15.2

P/B 1.2

Current Price ₹110

Book Value ₹ 92.4

Face Value 1

52W High ₹149

Dividend Yield 0.45%

52W Low ₹ 71

Edit Ratio

Bliss GVS Pharma Research see more...

Overview Inc. Year: 1984Industry: Pharmaceuticals & Drugs

Bliss GVS Pharma Ltd develops, manufactures, and markets pharmaceutical formulations in India. It gives pharma merchandise, such as drugs, creams/gels/ointments, dry powder for injections and oral suspensions, effervescent capsules, eye/ear drops, injections, liquid arrangements, creams, lozenges, nasal solutions, oral solids, parenterals, pessaries, sachets, tender gelatin tablets, suppositories, suspensions, syrups, capsules, topical preparation, and transdermal patches. The company additionally gives other healthcare merchandise, consisting of balms, creams, lozenges, nasal inhalers, lotions, over-the-counter products, petroleum jellies, powders, roll-ons, shampoos, soaps, sprays, syrups, solutions and vaginal washes. In addition, it gives healing products together with anti-bacterial, anti-dandruff shampoo, amino acid training, iron tonic, antitussive, appetite stimulant, anti-allergic, body supplement, anti-biotic, anti-diabetic, anti-diarrheal, anti-emetic, anti-fungal, anti-haemorrhoidal, anti-helmintic, anti-infective, anti-inflammatory, anti-malarial, anti-microbial, anti-migraine, anti-oxidant, anti-protozoal, ear wax solvent, anti-pyretic, anti-septic, anti-spasmodic, anti-ulcer, and anti-ulcerant; and analgesic, oral rehydration, antacid, anxiolytic, appetizer, cough syrup, erectile disorder, haematinic, hand sanitizer, health complement, insecticide, laryngitis, pharyngitis, laxative, lubricant, mosquito repellant, nasal decongestant, dietary complement, moisturizer, prickly heat powder, pores and skin lightening lotion, vaginal contraceptive, vaginal hygiene, and nutrition dietary supplements, as well as medicated, complexion, moisturizing, and overall protection soaps. The corporation also exports its merchandise. Bliss GVS Pharma Ltd changed into incorporated in 1984 and is primarily based in Mumbai, India.

Read More..

Bliss GVS Pharma Share Price

New

₹ | |

Volume
Price

Quarterly Price

Quarterly Monthly
Show Value Show %

Peer Comparison

Bliss GVS Pharma Quarterly Results

#(Fig in Cr.) Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
Net Sales 216 167 189 172 206 185 160 212 201 198
Other Income 6 12 7 2 6 3 5 13 5 6
Total Income 222 179 196 175 211 188 165 224 206 204
Total Expenditure 182 147 150 148 158 179 135 158 157 170
Operating Profit 40 32 46 27 53 9 29 67 49 34
Interest 1 2 2 2 1 5 1 1 2 2
Depreciation 4 4 5 5 5 5 6 6 7 7
Exceptional Income / Expenses -74 0 0 0 0 0 0 0 0 -29
Profit Before Tax -39 26 39 20 47 -1 22 59 40 -4
Provision for Tax 10 3 12 4 18 -4 7 16 11 1
Profit After Tax -49 23 27 16 30 3 14 43 29 -5
Adjustments -2 -4 -2 -2 -2 -0 0 -1 -1 -4
Profit After Adjustments -50 20 26 14 28 3 15 42 28 -9
Adjusted Earnings Per Share -4.8 1.9 2.5 1.3 2.7 0.3 1.4 4.1 2.6 -0.9

Bliss GVS Pharma Profit & Loss

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
Net Sales 397 345 407 547 798 815 899 689 577 747 752 771
Other Income 14 28 20 24 13 27 38 39 22 31 18 29
Total Income 411 373 427 571 811 841 936 728 599 779 769 799
Total Expenditure 285 273 304 391 596 618 741 566 471 629 634 620
Operating Profit 125 99 124 180 215 224 195 163 129 150 135 179
Interest 10 18 16 19 20 23 4 8 7 5 10 6
Depreciation 6 11 11 13 20 21 9 13 17 17 19 26
Exceptional Income / Expenses 0 0 0 0 0 -34 0 -13 0 -74 0 -29
Profit Before Tax 109 71 96 148 175 145 182 129 104 54 106 117
Provision for Tax 50 30 35 48 63 57 55 34 30 31 29 35
Profit After Tax 60 41 61 100 113 89 127 95 74 23 77 81
Adjustments -2 -0 -1 -18 -31 -30 -3 2 -5 -8 -6 -6
Profit After Adjustments 58 41 60 82 82 59 124 97 68 15 71 76
Adjusted Earnings Per Share 5.6 4 5.8 8 8 5.7 12 9.4 6.6 1.5 6.8 7.2

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 1% 3% -2% 7%
Operating Profit CAGR -10% -6% -10% 1%
PAT CAGR 235% -7% -3% 3%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR 34% -3% -7% 9%
ROE Average 9% 7% 11% 17%
ROCE Average 12% 10% 15% 22%

Bliss GVS Pharma Balance Sheet

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Shareholder's Funds 258 287 337 413 487 536 646 736 808 819 884
Minority's Interest 14 10 15 33 66 11 14 15 20 28 34
Borrowings 91 88 57 38 26 6 33 37 33 23 41
Other Non-Current Liabilities 6 8 10 11 7 7 5 9 13 6 2
Total Current Liabilities 202 308 243 379 437 299 207 231 204 233 193
Total Liabilities 571 700 662 874 1023 860 905 1027 1077 1109 1154
Fixed Assets 168 213 234 225 304 136 145 241 234 281 378
Other Non-Current Assets 51 16 10 66 153 34 66 17 78 51 78
Total Current Assets 349 469 417 583 566 690 693 770 765 777 697
Total Assets 571 700 662 874 1023 860 905 1027 1077 1109 1154

Bliss GVS Pharma Cash Flow

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Opening Cash & Cash Equivalents 58 28 39 5 0 47 37 15 15 13 22
Cash Flow from Operating Activities 7 41 38 113 289 18 40 47 64 135 34
Cash Flow from Investing Activities -124 -11 -29 -50 -231 50 -74 -48 -47 -93 -8
Cash Flow from Financing Activities 110 -8 -42 -40 -10 -76 17 -6 -21 -24 -25
Net Cash Inflow / Outflow -8 22 -33 23 48 -8 -17 -7 -4 19 2
Closing Cash & Cash Equivalent 50 50 5 28 47 37 15 15 13 22 25

Bliss GVS Pharma Ratios

# Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Earnings Per Share (Rs) 5.6 3.97 5.81 8 7.95 5.7 11.99 9.43 6.64 1.45 6.8
CEPS(Rs) 6.36 5.01 7.05 10.99 12.88 10.67 13.15 10.46 8.84 3.9 9.16
DPS(Rs) 0.7 0.5 0.7 0.5 0.6 1 1 0.5 0.5 0.5 0.5
Book NAV/Share(Rs) 24.78 27.67 32.64 40 47.18 51.99 62.63 71.32 77.41 78.01 84.01
Core EBITDA Margin(%) 27.91 20.53 25.25 28.34 25.27 24.18 17.54 17.89 18.48 15.83 15.61
EBIT Margin(%) 29.93 25.52 27.45 30.36 24.32 20.62 20.74 19.81 19.29 7.88 15.49
Pre Tax Margin(%) 27.49 20.34 23.44 26.97 21.86 17.82 20.24 18.71 18.04 7.25 14.11
PAT Margin (%) 14.96 11.83 14.99 18.22 14.04 10.88 14.1 13.82 12.82 3.09 10.21
Cash Profit Margin (%) 16.47 14.91 17.75 20.64 16.55 13.5 15.09 15.64 15.8 5.41 12.69
ROA(%) 13.53 6.46 9.01 13.04 11.88 9.42 14.35 9.86 7.03 2.12 6.78
ROE(%) 25.56 15.17 19.74 26.73 25.06 17.34 21.43 13.79 9.64 2.88 9.11
ROCE(%) 36.18 20.56 23.57 32.07 31.06 24.61 26.58 17.02 12.49 6.37 12.22
Receivable days 171.03 241.81 206.07 182.13 126.33 123.8 154.2 267.05 319.89 209.14 188.89
Inventory Days 20.71 34.22 29.51 24.04 20.01 24.25 27.7 40.11 54.72 54.42 55.12
Payable days 172.07 277.19 194.35 145.29 105.12 73.11 40.93 70.02 90.85 77.87 81.4
PER(x) 4.77 11.2 22.21 15.86 22.18 34.28 15 10.69 14.86 53.04 10.47
Price/Book(x) 1.08 1.61 3.95 3.17 3.74 3.76 2.87 1.41 1.28 0.99 0.85
Dividend Yield(%) 2.62 1.12 0.54 0.39 0.34 0.51 0.56 0.5 0.51 0.65 0.7
EV/Net Sales(x) 0.94 1.6 3.52 2.49 2.37 2.51 2.06 1.53 1.72 0.97 0.98
EV/Core EBITDA(x) 2.98 5.56 11.58 7.56 8.8 9.14 9.48 6.51 7.72 4.84 5.46
Net Sales Growth(%) 48.51 -13.11 18.13 34.33 45.99 2.03 10.3 -23.29 -16.26 29.5 0.55
EBIT Growth(%) 42.84 -25.72 26.98 48.37 16.96 -13.84 10.85 -26.72 -18.43 -47.11 97.66
PAT Growth(%) 13.42 -31.14 49.63 63.12 12.52 -21.32 42.86 -24.8 -22.34 -68.74 231.8
EPS Growth(%) 9.86 -28.98 46.15 37.68 -0.53 -28.35 110.46 -21.38 -29.58 -78.15 368.97
Debt/Equity(x) 0.58 0.6 0.47 0.32 0.46 0.22 0.16 0.16 0.15 0.13 0.11
Current Ratio(x) 1.73 1.53 1.72 1.54 1.29 2.3 3.35 3.34 3.76 3.33 3.61
Quick Ratio(x) 1.56 1.42 1.58 1.44 1.18 2.11 2.98 3.02 3.27 2.8 3.08
Interest Cover(x) 12.27 4.92 6.85 8.96 9.91 7.37 42.21 18.04 15.38 12.42 11.23
Total Debt/Mcap(x) 0.54 0.38 0.12 0.1 0.12 0.06 0.05 0.12 0.12 0.13 0.13

Bliss GVS Pharma Shareholding Pattern

# Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
Promoter 33.14 33.14 34.51 34.55 34.46 35.04 35.12 35.06 34.97 34.97
FII 19.59 17.33 17.17 16.68 16.53 16.6 16.5 16.31 15.35 14.73
DII 6.66 6.66 6.65 6.64 6.63 6.63 6.62 6.61 6.61 6.59
Public 40.61 42.87 41.67 42.13 42.38 41.73 41.75 42.01 43.08 43.71
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Pros

  • Company is almost debt free.

Cons

  • Promoter holding is low: 34.97%.
  • Company has a low return on equity of 7% over the last 3 years.
  • Debtor days have increased from 77.87 to 81.4days.
  • The company has delivered a poor profit growth of -2% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Bliss GVS Pharma News

IPO

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

You May Also Know About

Unlisted Shares Pre-IPO Shares ESOP Shares Delisted Shares

Please Login!

Click to Login
OR
Get free Account

Error!